Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV

We evaluated quadrivalent human papillomavirus vaccineseroresponses among 35 girlsliving with HIV (9-13 years of ages) and compared with data on girlswithout HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccinewas safe and well tolerated. However, antibody response was significantly lower in girlsliving with HIV relative to girlswithout HIV. HIV virologicsuppression predicted better antibody response.